Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) A different disease but shows that the proteins can be reduced. Also interesting that it needs weekly injections. Also I like the quote:
"This approval represents a significant advancement for the patients, families, caregivers and healthcare professionals in the U.S. who need more options for the medical management of this disease."
Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
https://globenewswire.com/news-release/2018/10/05/1617653/0/en/Akcea-and-Ionis-Receive-FDA-Approval-of-TEGSEDI-inotersen-for-the-Treatment-of-the-Polyneuropathy-of-Hereditary-Transthyretin-Mediated-Amyloidosis-in-Adults.html